Close

Seres Therapeutics (MCRB) Announces SER-109 Phase 1b/2 Data Published in The Journal of Infectious Diseases

February 9, 2016 7:37 AM EST Send to a Friend
Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics company, announced that positive results from the Phase 1b/2 study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login